

Company Overview

Conversion Labs, Inc. (OTCQB: IMMD) develops, manufactures, and commercializes innovative health and wellness products that address large unmet needs in the marketplace. We focus on superior, scientifically supported consumer products and unparalleled branding & marketing.

Conversion Labs's product portfolio consists of consumer brands based on sound science and understood mechanisms, and a bulk, raw material manufacturing business, including:

- Shapiro MD™, a patented, natural occurring DHT-blocking shampoo and conditioner that has been shown to significantly help hair loss.
- iNR Wellness™, a proprietary immune support and full-body wellness supplement containing the Company's high-grade Yeast Beta-1,3/1,6 D-glucan.
- Nayad™, a complete skincare product line containing the Company's high-grade Yeast Beta-1,3/1,6 D-glucan.
- Unbranded, raw bulk Yeast Beta-1,3/1,6-D-glucans, for both topical and oral applications, sold to top-tier cosmetic and nutritional companies.

Our proprietary, patented, and clinically researched Yeast Beta-1,3/1,6-D-glucans are respected and used internationally by well-known consumer brands. Yeast Beta-1,3/1,6-D-glucan has been shown in hundreds of clinical studies to be a powerful immune modulator with potent antioxidant properties. In skincare, clinical studies have demonstrated that topical Yeast Beta-1,3/1,6-D-glucan stimulates Langerhans cells (the skin's immune cells) and may have anti-aging properties.

In 2016 with the launch of new consumer-facing brands, Conversion Labs grew its business by over 300%, to top-line revenue of \$5.23 million, the highest in its history. Most importantly, Conversion Labs committed significant resources in 2016 to building a world-class direct-marketing infrastructure that will be used to further grow and launch our consumer brands in 2017 and 2018.

Highlights

- 70% top-line growth in 2015; 330% growth in 2016
- Product portfolio that addresses large, multi-billion dollar markets
- Emerging revenue and customer acquisition model
- 34 million common shares outstanding at year-end 2016
- Talented leadership team with strong track record of creating shareholder value

Immudyne Acquires 51% of PDFSimpli With Proceeds From Direct Institutional Investment

Jun 1 2018, 8:00 AM EDT

Management Team

Justin Schreiber

President, Chief Executive Officer, Director

Stefan Galluppi

Chief Operating Officer, Chief Technology Officer, Director

Robert Kalkstein

Chief Financial Officer

Joseph V. DiTrollo, MD

Chief Medical Officer - U.S., Director

Sven Rohmann, MD, PhD, MBA

Global Chief Medical Officer – Europe.

Stock Overview

Symbol	CVLB
Exchange	OTCQB
Market Cap	9.3m
Last Price	\$0.215
52-Week	\$0.181 - \$0.54

06/21/2018 12:20 PM EDT

Conversion Labs, Inc.

1460 Broadway
New York, NY 10036

Investor Relations

T: 866-351-5907 Ext: 5

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

